Compare MTW & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTW | REPL |
|---|---|---|
| Founded | 1902 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 498.8M | 407.1M |
| IPO Year | 1994 | 2018 |
| Metric | MTW | REPL |
|---|---|---|
| Price | $13.56 | $11.09 |
| Analyst Decision | Sell | Hold |
| Analyst Count | 4 | 9 |
| Target Price | ★ $10.50 | $5.67 |
| AVG Volume (30 Days) | 263.8K | ★ 3.2M |
| Earning Date | 05-05-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,240,900,000.00 | N/A |
| Revenue This Year | $4.73 | N/A |
| Revenue Next Year | $2.98 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.89 | N/A |
| 52 Week Low | $9.09 | $1.50 |
| 52 Week High | $15.56 | $12.50 |
| Indicator | MTW | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 57.63 | 61.12 |
| Support Level | $12.23 | $9.69 |
| Resistance Level | $14.40 | $12.50 |
| Average True Range (ATR) | 0.50 | 0.70 |
| MACD | 0.03 | -0.16 |
| Stochastic Oscillator | 99.35 | 72.37 |
Manitowoc Co Inc provides engineered lifting solutions. It designs and manufactures mobile telescopic cranes, tower cranes, lattice-boom crawler cranes, and boom trucks. It offers products under brand names such as Grove, Manitowoc, National Crane, Potain, Shuttlelift, and Manitowoc Crane Care. Its crane products serve dealers, rental companies, contractors, and government entities in diverse markets, including energy production/distribution and utility, petrochemical and industrial, infrastructure, and commercial/residential construction. Manitowoc has three reportable segments: the Americas, Europe and Africa, and the Middle East and Asia-Pacific. The Americas segment generates the majority of the revenue for the company.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.